SCHOTT Pharma AG & Co. KGaA
1SXPGermany
8 filed reports · 129 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
8 reports · Sep 2024 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| AnnualBundesanzeiger | 2 | 132 | Sep 2024 to Sep 2025 |
| Half YearBundesanzeiger | 2 | 250 | Mar 2025 to Mar 2026 |
| Q1Bundesanzeiger | 2 | 71 | Dec 2024 to Dec 2025 |
| Q3Bundesanzeiger | 2 | 241 | Jun 2025 to Jun 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q3 | q3 | Jun 30, 2026 | Jun 30, 2026 | 134 | Open |
| FY2026 Q2 | half year | Mar 31, 2026 | Mar 31, 2026 | 131 | Open |
| FY2026 Q1 | q1 | Dec 31, 2025 | Dec 31, 2025 | 31 | Open |
| FY2025 | annual | Sep 30, 2025 | Sep 30, 2025 | 93 | Open |
| FY2025 Q3 | q3 | Jun 30, 2025 | Jun 30, 2025 | 107 | Open |
| FY2025 Q2 | half year | Mar 31, 2025 | Mar 31, 2025 | 119 | Open |
| FY2025 Q1 | q1 | Dec 31, 2024 | Dec 31, 2024 | 40 | Open |
| FY2024 | annual | Sep 30, 2024 | Sep 30, 2024 | 39 | Open |
Financial data
129 concepts · 694 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
IFRS123 concepts · 680 facts · Sep 2024 to Jun 2026
- Contract liabilities¹11 · Sep 2024 to Jun 2026
- Other provisions11 · Sep 2024 to Jun 2026
- Revenue11 · Mar 2025 to Jun 2026
- Cost of Revenue10 · Mar 2025 to Jun 2026
- Income Tax Expense (Benefit)10 · Mar 2025 to Jun 2026
- Other non-financial assets10 · Sep 2024 to Jun 2026
- EPS (Basic)9 · Mar 2025 to Jun 2026
- EPS (Diluted)9 · Mar 2025 to Jun 2026
- Financial result9 · Mar 2025 to Jun 2026
- General administrative expenses9 · Mar 2025 to Jun 2026
- Gross Profit9 · Mar 2025 to Jun 2026
- Interest Expense9 · Mar 2025 to Jun 2026
- Interest income9 · Mar 2025 to Jun 2026
- Net Income9 · Mar 2025 to Jun 2026
- Net other financial result9 · Mar 2025 to Jun 2026
- Operating income (EBIT)9 · Mar 2025 to Jun 2026
- Other operating income9 · Mar 2025 to Jun 2026
- Profit before income taxes9 · Mar 2025 to Jun 2026
- Research and development costs9 · Mar 2025 to Jun 2026
- Selling and Marketing Expense9 · Mar 2025 to Jun 2026
- Share of profit from investments accounted for using the equity method9 · Mar 2025 to Jun 2026
- thereof attributable to limited liability shareholders of SCHOTT Pharma AG & Co. KGaA9 · Mar 2025 to Jun 2026
- thereof attributable to non-controlling interests9 · Mar 2025 to Jun 2026
- Accounts Payable8 · Sep 2024 to Jun 2026
Segment2 concepts · 10 facts · Mar 2026 to Jun 2026
- Revenue8 · Mar 2026 to Jun 2026
- Drug Containment Solutions (DCS)2 · Jun 2026
KPI3 concepts · 3 facts · Mar 2026 to Jun 2026
- Gross profit margin1 · Jun 2026
- HVS revenue share1 · Jun 2026
- Tax rate1 · Mar 2026
APM1 concepts · 1 facts · Jun 2026
- Total1 · Jun 2026
Segments
10 factsFigures broken down by business line, region, product or another axis the company reports on.
Business segment2 members · 4 facts
- Drug Containment Solutions (DCS)2 · Jun 2026
- Drug Delivery Systems (DDS)2 · Jun 2026
Geography4 members · 4 facts
- Asia and South Pacific1 · Jun 2026
- EMEA1 · Jun 2026
- North America1 · Jun 2026
- South America1 · Jun 2026
Solution type2 members · 2 facts
- Core1 · Mar 2026
- High-value solutions (HVS)1 · Mar 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.